CD4CAR T-cell therapy (CD4-directed chimeric antigen receptor T cells)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-24 — Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.: Phase I single-arm open-label 3+3 trial initiated to evaluate safety and feasibility of CD4-directed CAR-T cells as second-line therapy in relapsed/refractory CMML (trial-early, first-in-class application targeting CD4+ monocytic cells). (novelty: 4)
Open questions
Related
Contributing findings
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
24-jun-2026
novelty 4
per-area 4
introduces